NCT04750473View on ClinicalTrials.gov

Fluciclovine and PSMA PET/CT for the Classification and Improved Staging of Invasive Lobular Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 16, 2021

Primary Completion Date

March 21, 2023

Study Completion Date

March 21, 2024

Conditions
Anatomic Stage IV Breast Cancer AJCC v8Invasive Breast Lobular CarcinomaMetastatic Breast Lobular CarcinomaPrognostic Stage IV Breast Cancer AJCC v8
Interventions
PROCEDURE

Computed Tomography

Undergo PET/CT scan

DRUG

Fluciclovine F18

Given IV

DRUG

Gallium Ga 68 Gozetotide

Given IV

PROCEDURE

Positron Emission Tomography

Undergo PET/CT scan

Trial Locations (1)

30322

Emory University Hospital/Winship Cancer Institute, Atlanta

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

National Institutes of Health (NIH)

NIH

lead

Emory University

OTHER

NCT04750473 - Fluciclovine and PSMA PET/CT for the Classification and Improved Staging of Invasive Lobular Breast Cancer | Biotech Hunter | Biotech Hunter